bicalutamide has been researched along with abiraterone acetate in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 8 (88.89) | 2.80 |
| Authors | Studies |
|---|---|
| Bevan, CL; Brooke, GN; Fioretti, FM; Sita-Lumsden, A | 1 |
| Akamatsu, S; Fujimoto, Y; Inoue, T; Kimura, T; Kobayashi, T; Matsubara, N; Mori, K; Murakami, K; Ogawa, O; Terada, N | 1 |
| Grellety, T | 1 |
| Kolesar, JM; Momo, HD; Myint, ZW; Otto, DE; Wang, P; Yan, D | 1 |
| Fujihara, A; Hongo, F; Ito, S; Matsugasumi, T; Ohashi, M; Okihara, K; Shiraishi, T; Ueda, T; Ukimura, O; Yamada, Y | 1 |
| Egawa, S; Enei, Y; Fukuokaya, W; Hata, K; Iwamoto, Y; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Obayashi, K; Onuma, H; Otsuka, T; Sakanaka, K; Sano, T; Shimomura, T; Suzuki, H; Tsuzuki, S; Yanagisawa, T | 1 |
| Ito, T; Koie, T; Miyake, H; Naiki, T; Nakane, K; Shiroki, R; Sugiyama, Y; Takahara, K; Yasui, T | 1 |
| Kanao, K; Kaneko, G; Nishimoto, K; Okabe, T; Oyama, M; Shirotake, S; Takahashi, T; Umezawa, Y | 1 |
| Fujihara, A; Fujita, K; Hongo, F; Kayukawa, N; Minami, T; Miyashita, M; Nakamura, Y; Nishimoto, M; Ogura, R; Okihara, K; Sako, S; Shiraishi, T; Ueda, T; Uemura, H; Ukimura, O; Yoshimura, K | 1 |
3 review(s) available for bicalutamide and abiraterone acetate
| Article | Year |
|---|---|
Revising the role of the androgen receptor in breast cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Androstadienes; Anilides; Estrogen Antagonists; Female; Humans; Nitriles; Receptors, Androgen; Receptors, Estrogen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tamoxifen; Tosyl Compounds; Triple Negative Breast Neoplasms | 2014 |
[Androgen receptor-positive triple negative breast cancer: From biology to therapy].
Topics: Abiraterone Acetate; Age Factors; Aged; Androgen Antagonists; Anilides; Benzamides; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Female; Forecasting; Humans; Mutation; Nitriles; Phenylthiohydantoin; Prognosis; Rare Diseases; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Triple Negative Breast Neoplasms | 2020 |
Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.
Topics: Abiraterone Acetate; Accidental Falls; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Case-Control Studies; Fractures, Bone; Humans; Incidence; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Risk Factors; Thiohydantoins; Tosyl Compounds; Trauma Severity Indices | 2020 |
6 other study(ies) available for bicalutamide and abiraterone acetate
| Article | Year |
|---|---|
Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Flutamide; Follow-Up Studies; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds | 2020 |
Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Grading; Nitriles; Oligopeptides; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome | 2021 |
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Humans; Japan; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Nonsteroidal Anti-Androgens; Prednisolone; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Tosyl Compounds | 2022 |
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Androstenes; Anilides; Antineoplastic Combined Chemotherapy Protocols; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds | 2022 |
Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Hormones; Humans; Male; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |